Our results have demonstrated that monensin acts synergistically with tyrosine kinase and EGFR inhibitors, as well as currently-utilized agents such as oxaliplatin, to suppress proliferation of ovarian cancer cells. Here, EGFR is linked to ovarian carcinoma.